Preferred Label : pembrolizumab;
CISMeF synonym : MK-3475; lambrolizumab;
Is substance : O;
UNII : DPT0O3T46P;
Origin ID : C582435;
UMLS CUI : C3658706;
ATC code(s)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Exact mapping(s) to DCI
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also (suggested by CISMeF)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-marr/pembrolizumab
2024
false
false
false
France
French
risk management
pembrolizumab
Infusion related reaction
immune system diseases
Drug-Related side effects and adverse reactions
patient education handout
pregnancy
continuity of patient care
drug monitoring
Antineoplastic Agents, Immunological
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3546684/fr/keytruda-pembrolizumab-carcinome-urothelial
2024
false
false
false
France
urologic neoplasms
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
enfortumab vedotin
adult
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
pembrolizumab
evaluation of the transparency committee
carcinoma
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3420797/fr/keytruda-pembrolizumab-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
breast neoplasms
pembrolizumab
breast cancer
pembrolizumab
Childhood Breast Carcinoma
Pembrolizumab
neoplasm, malignant
Male Breast Carcinoma
Keytruda
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3546934/fr/keytruda-pembrolizumab-cancer-du-rein-en-adjuvant
2024
false
false
false
France
Clear Cell Renal Cell Carcinoma
carcinoma, renal cell
treatment outcome
insurance, health, reimbursement
adult
Antineoplastic Agents, Immunological
pembrolizumab
Adjuvant Therapy
nephrectomy
risk
recurrence
evaluation of the transparency committee
pembrolizumab
---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following
nephrectomy and resection of metastatic lesions
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma
---
https://www.has-sante.fr/jcms/p_3409403/fr/keytruda-pembrolizumab-carcinome-a-cellule-renale
2023
false
false
false
France
chemotherapy, adjuvant
treatment outcome
insurance, health, reimbursement
pembrolizumab
infusions, intravenous
Antineoplastic Agents, Immunological
clear cell renal cell carcinoma
nephrectomy
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following
nephrectomy and resection of metastatic lesions
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://www.has-sante.fr/jcms/p_3396878/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2023
false
false
false
France
triple negative breast neoplasms
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
pembrolizumab
antineoplastic combined chemotherapy protocols
infusions, intravenous
Locally Advanced Triple-Negative Breast Carcinoma
Early Stage Triple-Negative Breast Carcinoma
locally advanced triple negative breast cancer at high risk of recurrence
early stage triple negative breast cancer at high risk of recurrence
evaluation of the transparency committee
pembrolizumab
---
Summary Safety Review - Keytruda (pembrolizumab) and Tecentriq (atezolizumab) - Assessing
the Potential Risk of Aplastic Anemia
https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1691503886633
2023
false
false
false
Canada
French
drug evaluation
Drug-Related side effects and adverse reactions
pembrolizumab
antibodies, monoclonal, humanized
atezolizumab
Antineoplastic Agents, Immunological
risk assessment
anemia, aplastic
Immune Checkpoint Inhibitors
canada
pharmacovigilance note
---
https://www.has-sante.fr/jcms/p_3395770/fr/keytruda-pembrolizumab-melanome-de-stade-iib-iic-ou-iii
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
adolescent
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIC Cutaneous Melanoma AJCC v6 and v7
melanoma
Stage III Cutaneous Melanoma AJCC v7
Advanced Cutaneous Melanoma
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
melanoma
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3334585/fr/keytruda-pembrolizumab-cancer-de-l-endometre
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
infusions, intravenous
pembrolizumab
Antineoplastic Agents, Immunological
adult
Lenvatinib/Pembrolizumab Regimen
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
neoplasm metastasis
economic evaluation
evaluation of the transparency committee
endometrial neoplasms
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3338759/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
pembrolizumab
PD-L1 Positive
adult
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Recurrent Triple-Negative Breast Carcinoma
Antineoplastic Agents, Immunological
programmed cell death 1 receptor
evaluation of the transparency committee
pembrolizumab
triple negative breast neoplasms
---
https://www.has-sante.fr/jcms/p_3367810/fr/keytruda-pembrolizumab-cancer-du-col-de-l-uterus
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
uterine cervical neoplasms
Antineoplastic Agents, Immunological
pembrolizumab
pembrolizumab
infusions, intravenous
adult
antineoplastic combined chemotherapy protocols
package leaflet
summary of product characteristics
guidelines for drug use
neoplasm recurrence, local
neoplasm metastasis
PD-L1 Positive
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3374922/fr/keytruda-pembrolizumab-cancer-du-col-de-l-uterus
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
pembrolizumab
infusions, intravenous
Antineoplastic Agents, Immunological
adult
neoplasm metastasis
neoplasm recurrence, local
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
uterine cervical neoplasms
pembrolizumab
cancer of the uterine cervix
---
https://www.has-sante.fr/jcms/p_3313589/fr/keytruda-25-mg/ml-pembrolizumab
2022
false
false
false
France
antibodies, monoclonal, humanized
insurance, health, reimbursement
adult
esophageal neoplasms
Adenocarcinoma of the gastroesophageal junction
HER2 negative
treatment outcome
Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma
antineoplastic combined chemotherapy protocols
Metastatic Gastroesophageal Junction Adenocarcinoma
Siewert type I adenocarcinoma of esophagogastric junction (disorder)
pembrolizumab
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3390429/fr/keytruda-pembrolizumab-cancer-du-sein
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
pembrolizumab
evaluation of the transparency committee
triple negative breast neoplasms
pembrolizumab
---
https://pgtmsite.files.wordpress.com/2024/01/ad-pembro_rapport-final1.pdf
2022
Canada
drug information
neoplasm, malignant
quebec
pembrolizumab
carcinoma, non-small-cell lung
Nonmetastatic
CYRIB wt Allele
L1 Stage Finding
Metastatic
Daur Chinese
lupus erythematosus cell
Lower Esophageal Sphincter
Lung Non-Small Cell Carcinoma
metastatic to
L1 Mouse
small cell lung carcinoma
patients
Patient
has patient
LE cells
Due
Long Interspersed Nucleotide Element-1
Pembrolizumab
Identifier
Intent To Treat
Device-In-Use Domain
Metastatic Malignant Neoplasm
Deoxyuridine
B7-H1 Antigen
pembrolizumab
pembrolizumab
intention to treat analysis
Analysis
hospitals, university
neutrophils
Cancer Therapeutic Procedure
Analyzed
Description
INRG Stage L1
---
https://www.has-sante.fr/jcms/p_3325988/fr/keytruda-pembrolizumab-cancer-du-sein
https://www.has-sante.fr/jcms/p_3325999/fr/decision-n-2022-0084/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
breast cancer
breast neoplasms
Keytruda
pembrolizumab
pembrolizumab
pembrolizumab
Breast cancer
neoplasm, malignant
---
https://www.has-sante.fr/jcms/p_3325579/fr/keytruda-pembrolizumab-cancer-de-l-endometre
https://www.has-sante.fr/jcms/p_3325589/fr/decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
https://www.has-sante.fr/jcms/p_3329013/fr/decision-n-2022-0109/dc/sem-du-31-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2022-0085/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
French
evaluation of the transparency committee
pembrolizumab
cancer
neoplasm, malignant
Endometrium cancer
Keytruda
endometrium
pembrolizumab
Endomet
endometrial neoplasms
pembrolizumab
---
https://www.has-sante.fr/jcms/p_3327389/fr/keytruda-pembrolizumab-cancer-de-l-œsophage
https://www.has-sante.fr/jcms/p_3327401/fr/decision-n-2022-0182/dp/sem-du-30-mars-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-keytruda
2022
false
false
false
France
evaluation of the transparency committee
Esophagus cancer
Esophagus
pembrolizumab
esophagospasm
cancer of esophagus
Keytruda
neoplasm, malignant
pembrolizumab
Esophagus
pembrolizumab
esophageal neoplasms
---
https://www.has-sante.fr/jcms/p_3296560/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2021
France
evaluation of the transparency committee
Keytruda
Breast cancer
pembrolizumab
triple negative breast neoplasms
pembrolizumab
breast cancer
neoplasm, malignant
pembrolizumab
triplets
---
https://pgtmsite.files.wordpress.com/2024/01/mic_ad-pembro_final-1.pdf
2021
Canada
drug information
Ambulatory Care Facility
pembrolizumab
Clinical Batch
Clinical Lot
pembrolizumab
Clinical Data
Pembrolizumab
Clinical Relevance
pembrolizumab
Intervention Model
---
https://www.has-sante.fr/jcms/p_3272286/fr/keytruda-pembrolizumab-cancer-colorectal-metastatique
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
pembrolizumab
colorectal neoplasms
neoplasm metastasis
Metastatic malignant neoplasm to colon and/or rectum (disorder)
adult
Antineoplastic Agents, Immunological
Unresectable Colorectal Carcinoma
infusions, intravenous
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3289694/fr/keytruda-25-mg/ml-pembrolizumab-lymphome-de-hodgkin
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
pembrolizumab
adult
recurrence
hodgkin disease
Antineoplastic Agents, Immunological
infusions, intravenous
child
adolescent
aged
pembrolizumab
Adult Hodgkin Lymphoma
Childhood Hodgkin Lymphoma
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3245422/fr/keytruda-cbnpc-2eme-ligne
2021
false
false
false
France
pembrolizumab
Antineoplastic Agents, Immunological
insurance, health, reimbursement
treatment outcome
adult
bronchial neoplasms
carcinoma, non-small-cell lung
PD-L1 Positive
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/choix-de-la-posologie-du-nivolumab-et-du-pembrolizumab.html
2020
Canada
guidelines for drug use
Nivolumab
pembrolizumab
pembrolizumab
nivolumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://pgtmsite.files.wordpress.com/2024/01/ad-anti-pd-1_final-corr.pdf
2020
false
false
false
Canada
technical report
quebec
pembrolizumab
has patient
Portal vein air
nivolumab
patients
neoplasm, malignant
cancer
Nivolumab
hospitals, university
neoplasms
pembrolizumab
Cancer
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3190303/fr/keytruda-carcinome-epidermoide-de-la-tete-et-du-cou-cetec
2020
false
false
false
France
French
evaluation of the transparency committee
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
pembrolizumab
pembrolizumab
pembrolizumab
adult
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
Squamous Cell Carcinoma of Head and Neck
neoplasm metastasis
neoplasm recurrence, local
B7-H1 Antigen
head and neck neoplasms
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3184677/fr/keytruda-cancer-du-rein
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
carcinoma, renal cell
antineoplastic combined chemotherapy protocols
Axitinib
Antineoplastic Agents, Immunological
pembrolizumab
infusions, intravenous
survival analysis
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/c_2906433/fr/keytruda-cancer-bronchique-non-a-petites-cellules-1ere-ligne
2020
false
false
false
France
pembrolizumab
antineoplastic combined chemotherapy protocols
Pemetrexed
platinum compounds
bronchial neoplasms
carcinoma, non-small-cell lung
adult
neoplasm metastasis
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3112911/fr/keytruda
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
pembrolizumab
pembrolizumab
Metastatic Lung Non-Small Cell Squamous Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
carcinoma, non-small-cell lung
adult
carcinoma, squamous cell
carboplatin
paclitaxel
Albumin-Bound Paclitaxel
infusions, intravenous
Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen
Carboplatin/Paclitaxel/Pembrolizumab Regimen
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Nivolumab_Pembrolizumab_Outil_Posologies-.pdf
2020
Canada
drug evaluation
pembrolizumab
Nivolumab
nivolumab
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://pgtmsite.files.wordpress.com/2024/01/protocole-ad-pembrolizumab_final.pdf
2020
Canada
drug information
pembrolizumab
pembrolizumab
pembrolizumab
Pembrolizumab Regimen
AD Regimen
---
https://www.has-sante.fr/jcms/p_3080470/fr/keytruda-tete-et-cou-2eme-ligne
2019
false
false
false
France
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
pembrolizumab
adult
neoplasm recurrence, local
neoplasm metastasis
infusions, intravenous
Antineoplastic Agents, Immunological
programmed cell death 1 receptor
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3117084/fr/keytruda
2019
false
false
false
France
pembrolizumab
pembrolizumab
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2892906/fr/keytruda
2019
false
false
false
France
French
treatment outcome
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3081878/fr/keytruda
2019
false
false
false
France
adult
melanoma
Adjuvant Chemotherapy
Antineoplastic Agents, Immunological
pembrolizumab
pembrolizumab
treatment outcome
infusions, intravenous
disease-free survival
recurrence
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/informations-de-securite/keytruda-pembrolizumab-v-restriction-dindication-dans-le-traitement-des-patients-adultes-atteints-dun-carcinome-urothelial-localement-avance-ou-metastatique-ineligibles-a-une-chimiotherapie-a-base-de-cisplatine
2018
false
false
false
France
French
guidelines for drug use
pembrolizumab
pembrolizumab
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Urothelial Carcinoma
survival analysis
infusions, intravenous
antineoplastic agents
urologic neoplasms
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2842744/fr/keytruda-pembrolizumab-anticorps-anti-pd1
2018
false
false
false
France
French
guidelines for drug use
treatment outcome
pembrolizumab
pembrolizumab
infusions, intravenous
pembrolizumab
hodgkin disease
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
programmed cell death 1 receptor
recurrence
hematopoietic stem cell transplantation
transplantation, autologous
adult
Refractory Hodgkin Lymphoma
survival analysis
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
Brentuximab Vedotin
---
https://pgtmsite.files.wordpress.com/2024/01/pembrolizumab_strategie-posologique.pdf
2018
Canada
drug information
pembrolizumab
Pembrolizumab
pembrolizumab
pembrolizumab
Strategy
---
https://www.has-sante.fr/portail/jcms/c_2825867/fr/keytruda-vessie-1ere-ligne
2018
false
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
urinary bladder neoplasms
Urothelial Neoplasm
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-carcinome-urothelial
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-pembrolizumab-anticorps-monoclonal-carcinome-urothelial
2018
false
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
pembrolizumab
treatment outcome
survival analysis
Urothelial Carcinoma
urologic neoplasms
infusions, intravenous
pembrolizumab
antineoplastic agents
antineoplastic agents
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1207
2018
false
false
false
false
Canada
French
critical appraisal or critical reading
Urothelial Carcinoma
Antineoplastic Agents, Immunological
survival analysis
urologic neoplasms
antineoplastic combined chemotherapy protocols
disease progression
programmed cell death 1 receptor
pembrolizumab
neoplasm recurrence, local
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
platinum compounds
comparative effectiveness research
immunotherapy
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2885795/fr/keytruda
2018
false
false
false
France
Antineoplastic Agents, Immunological
pembrolizumab
melanoma
adult
carcinoma, non-small-cell lung
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
---
KEYTRUDA (pembrolizumab) - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome
and Toxic Epidermal Necrolysis
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2017/62670a-fra.php
2017
false
false
false
Canada
French
English
pharmacovigilance note
pembrolizumab
pembrolizumab
infusions, intravenous
antineoplastic agents
stevens-johnson syndrome
epidermal necrolysis, toxic
guidelines for drug use
carcinoma, non-small-cell lung
melanoma
programmed cell death 1 receptor
Drug-Induced stevens johnson syndrome
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2774645/fr/keytruda-cbnpc-1ere-ligne
https://www.has-sante.fr/portail/jcms/c_2774645/fr/keytruda-pembrolizumab-anticorps-anti-pd1-cbnpc-1ere-ligne
2017
false
false
false
France
French
evaluation of the transparency committee
pembrolizumab
guidelines for drug use
pembrolizumab
treatment outcome
infusions, intravenous
programmed cell death 1 receptor
programmed cell death 1 receptor
neoplasm metastasis
carcinoma, non-small-cell lung
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2780761/fr/keytruda
2017
false
false
false
France
French
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2769037/fr/keytruda-pembrolizumab-anticorps-anti-pd1-melanome
2017
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
treatment outcome
melanoma
Advanced Malignant Neoplasm
pembrolizumab
melanoma
BRAF Gene Mutation
infusions, intravenous
antineoplastic agents
adult
neoplasm metastasis
pembrolizumab
programmed cell death 1 receptor
antibodies, monoclonal
antibodies, monoclonal, humanized
---
http://www.has-sante.fr/portail/jcms/c_2755875/fr/keytruda
https://www.has-sante.fr/portail/jcms/c_2755875/fr/keytruda-pembrolizumab-anticorps-anti-pd1-cbnpc-2eme-ligne
2017
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
Advanced Malignant Neoplasm
pembrolizumab
infusions, intravenous
antineoplastic agents
adult
neoplasm metastasis
carcinoma, non-small-cell lung
mutation
carcinoma, non-small-cell lung
EGFR Gene Mutation
ALK Gene Mutation
guidelines for drug use
pembrolizumab
programmed cell death 1 receptor
antibodies, monoclonal
antibodies, monoclonal, humanized
---
http://www.has-sante.fr/portail/jcms/c_2639673/fr/keytruda-pembrolizumab-anticorps-anti-pd1
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
treatment outcome
melanoma
Advanced Malignant Neoplasm
pembrolizumab
melanoma
BRAF Gene Mutation
infusions, intravenous
antineoplastic agents
adult
neoplasm metastasis
pembrolizumab
programmed cell death 1 receptor
antibodies, monoclonal
antibodies, monoclonal, humanized
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1079/852
2016
false
false
false
false
Canada
French
critical appraisal or critical reading
Advanced Malignant Neoplasm
Progression-Free survival
survival analysis
pembrolizumab
Metastatic Melanoma
comparative effectiveness research
antibodies, monoclonal, humanized
antibodies, monoclonal
multicenter studies as topic
programmed cell death 1 receptor
CTLA-4 antigen
melanoma
proto-oncogene proteins b-raf
Ipilimumab
Ipilimumab
pembrolizumab
melanoma
antibodies, monoclonal, humanized
antibodies, monoclonal
disease-free survival
---
https://www.ema.europa.eu/medicines/human/EPAR/Keytruda
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pembrolizumab
pembrolizumab
melanoma
Advanced Malignant Neoplasm
Unresectable Malignant Neoplasm
adult
antineoplastic agents
antineoplastic agents
infusions, intravenous
programmed cell death 1 receptor
drug monitoring
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug compounding
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00227
2015
false
false
false
Canada
French
pembrolizumab
pembrolizumab
drug information
antibodies, monoclonal, humanized
---
